BlackRock Amends Neurocrine Biosciences Stake (SC 13G/A)

Ticker: NBIX · Form: SC 13G/A · Filed: 2024-01-23T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, passive-investing

TL;DR

**BlackRock just updated its Neurocrine Biosciences stake, signaling a potential shift in institutional sentiment.**

AI Summary

BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in its ownership of Neurocrine Biosciences Inc. common stock as of December 31, 2023. This filing, Amendment No. 12, updates their previous disclosures regarding their passive investment in the biotechnology company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal shifts in their confidence or investment strategy for Neurocrine Biosciences, potentially influencing other investors.

Why It Matters

This filing shows BlackRock, a major institutional investor, updated its stake in Neurocrine Biosciences, which can influence market perception and investor confidence in the stock.

Risk Assessment

Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate significant risk.

Analyst Insight

An investor should note BlackRock's continued involvement as a passive holder, but this filing alone doesn't suggest a strong buy or sell signal. It's a routine update reflecting their position as of December 31, 2023.

Key Players & Entities

Forward-Looking Statements

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.

Who is the reporting person in this filing?

The reporting person is BlackRock, Inc., a major institutional investment manager.

What is the subject company whose securities are being reported?

The subject company is NEUROCRINE BIOSCIENCES INC, identified by CIK 0000914475 and CUSIP 64125C109.

What was the date of the event that triggered this filing?

The date of the event which required the filing of this statement was December 31, 2023.

What is the business address of the reporting person, BlackRock Inc.?

BlackRock Inc.'s business address is 50 HUDSON YARDS, NEW YORK, NY 10001.

From the Filing

EDGAR Filing Documents for 0001086364-24-001395 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] SEC Accession No. 0001086364-24-001395 Filing Date 2024-01-23 Accepted 2024-01-23 11:52:29 Documents 1 Document Format Files Seq Description Document Type Size 1 us64125c1099_012324.txt SC 13G/A 12029 Complete submission text file 0001086364-24-001395.txt 13839 Mailing Address 12780 EL CAMINO REAL SAN DIEGO CA 92130 Business Address 12780 EL CAMINO REAL SAN DIEGO CA 92130 (858) 617-7600 NEUROCRINE BIOSCIENCES INC (Subject) CIK : 0000914475 (see all company filings) EIN. : 330525145 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A | Act: 34 | File No.: 005-46089 | Film No.: 24551323 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences) Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance)

View on Read The Filing